



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Lenalidomide (Standard)

Cat. No.:	HY-A0003R
CAS No.:	191732-72-6
Molecular Formula:	C <sub>13</sub> H <sub>13</sub> N <sub>3</sub> O <sub>3</sub>
Molecular Weight:	259.26
Target:	Molecular Glues; Apoptosis; Ligands for E3 Ligase
Pathway:	PROTAC; Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

#### Description

Lenalidomide (Standard) is the analytical standard of Lenalidomide. This product is intended for research and analytical applications. Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells<sup>[1][2]</sup>.

### REFERENCES

- [1]. Omran A, et al. Effects of MRP8, LPS, and lenalidomide on the expressions of TNF- $\alpha$ , brain-enriched, and inflammation-related microRNAs in the primary astrocyte culture. *ScientificWorldJournal*. 2013 Sep 21;2013:208309.
- [2]. Kotla V, et al. Mechanism of action of lenalidomide in hematological malignancies. *J Hematol Oncol*. 2009 Aug 12;2:36.
- [3]. Lopez-Girona A, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. *Leukemia*. 2012 Nov;26(11):2326-35.
- [4]. Rozewski DM, et al. Pharmacokinetics and tissue disposition of lenalidomide in mice. *AAPS J*. 2012 Dec;14(4):872-82.
- [5]. Minzel W, et al. Small Molecules Co-targeting CKI $\alpha$  and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models. *Cell*. 2018 Sep 20;175(1):171-185.e25.
- [6]. Nagashima, Takeyuki, et al. PHARMACEUTICAL COMPOSITION COMPRISING BICYCLIC NITROGEN-CONTAINING AROMATIC HETEROCYCLIC AMIDE COMPOUND AS ACTIVE INGREDIENT. Patent. 20170360780A1.
- [7]. Krönke J, et al. Lenalidomide induces degradation of IKZF1 and IKZF3. *Oncoimmunology*. 2014 Jul 3;3(7):e941742.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA